Follow
Associate Professor Vilija G. Jokubaitis
Associate Professor Vilija G. Jokubaitis
Neuroimmunology Genomics and Prognostics Group Head, Monash University
Verified email at monash.edu
Title
Cited by
Cited by
Year
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
International Multiple Sclerosis Genetics Consortium*†, ANZgene, ...
Science 365 (6460), eaav7188, 2019
8202019
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
4512019
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ...
Brain 139 (9), 2395-2405, 2016
3872016
Geographical variations in sex ratio trends over time in multiple sclerosis
M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ...
PloS one 7 (10), e48078, 2012
2592012
Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis
VG Jokubaitis, T Spelman, T Kalincik, J Lorscheider, E Havrdova, ...
Annals of neurology 80 (1), 89-100, 2016
2042016
Defining reliable disability outcomes in multiple sclerosis
T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, ...
Brain 138 (11), 3287-3298, 2015
1992015
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
T Kalincik, V Vivek, V Jokubaitis, J Lechner-Scott, M Trojano, G Izquierdo, ...
Brain 136 (12), 3609-3617, 2013
1932013
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ...
Annals of Neurology 77 (3), 425-435, 2015
1852015
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, ...
The Lancet Neurology 16 (4), 271-281, 2017
1702017
Fingolimod after natalizumab and the risk of short-term relapse
VG Jokubaitis, V Li, T Kalincik, G Izquierdo, S Hodgkinson, R Alroughani, ...
Neurology 82 (14), 1204-1211, 2014
1552014
Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination
MD Binder, HS Cate, AL Prieto, D Kemper, H Butzkueven, MM Gresle, ...
Journal of Neuroscience 28 (20), 5195-5206, 2008
1422008
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis
A He, T Spelman, V Jokubaitis, E Havrdova, D Horakova, M Trojano, ...
JAMA neurology 72 (4), 405-413, 2015
1282015
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
T Kalincik, A Manouchehrinia, L Sobisek, V Jokubaitis, T Spelman, ...
Brain 140 (9), 2426-2443, 2017
1082017
Risk of relapse phenotype recurrence in multiple sclerosis
T Kalincik, K Buzzard, V Jokubaitis, M Trojano, P Duquette, G Izquierdo, ...
Multiple Sclerosis Journal 20 (11), 1511-1522, 2014
1002014
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude
J Lechner-Scott, B Spencer, T De Malmanche, J Attia, M Fitzgerald, ...
Multiple Sclerosis Journal 18 (7), 974-982, 2012
912012
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, EK Havrdova, D Horakova, G Izquierdo, A Prat, M Girard, ...
Journal of Neurology, Neurosurgery & Psychiatry 90 (4), 458-468, 2019
902019
Risk of secondary progressive multiple sclerosis: a longitudinal study
A Fambiatos, V Jokubaitis, D Horakova, E Kubala Havrdova, M Trojano, ...
Multiple Sclerosis Journal 26 (1), 79-90, 2020
802020
Epigenome-wide association studies: current knowledge, strategies and recommendations
MP Campagna, A Xavier, J Lechner-Scott, V Maltby, RJ Scott, ...
Clinical epigenetics 13, 1-24, 2021
792021
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
N Lizak, A Lugaresi, R Alroughani, J Lechner-Scott, M Slee, E Havrdova, ...
Journal of Neurology, Neurosurgery & Psychiatry 88 (3), 196-203, 2017
722017
Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years
T Kalincik, I Diouf, S Sharmin, C Malpas, T Spelman, D Horakova, ...
Neurology 96 (5), e783-e797, 2021
712021
The system can't perform the operation now. Try again later.
Articles 1–20